Trial reportJCI insight2020
l-Arginine supplementation in severe asthma.
Trial report in JCI insight, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study of L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Level
Supplementation With L-ornithine Increases Representation Density of CD68+ and CD163+ Macrophages in Human Periodontitis Gingiva and Can Modulate Macrophages Phenotypes. Randomized Controlled Pilot Trial
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Metabolite signatures associated with microRNA miR-143-3p serve as drivers of poor lung function trajectories in childhood asthma.EBioMedicine · 2024Pooled it
- Acute L-Citrulline Supplementation Increases Nitric Oxide Bioavailability but Not Inspiratory Muscle Oxygenation and Respiratory Performance.Nutrients · 2021Trial
- Independent Associations Between Arginine-Related Metabolites and Disease Activity in Pediatric Asthma: A Multivariable Biomarker Study.Biomolecules · 2026Article
- L-arginine overdose is a potential risk factor for myocardial injury in patients with type 2 diabetes.World journal of diabetes · 2025Article
- Therapeutic Potential of Arginine-Loaded Red Blood Cell Nanovesicles Targeting Obese Asthma.Mediators of inflammation · 2025Article
- Obesity-related Asthma: A Pathobiology-based Overview of Existing and Emerging Treatment Approaches.American journal of respiratory and critical care medicine · 2024Review
- Consistent Multi-Omic Relationships Uncover Molecular Basis of Pediatric Asthma IgE Regulation.medRxiv : the preprint server for health sciences · 2024Article
- Changes in FeNO, d-ROMs, and BHJournal of asthma and allergy · 2024Article
- Amino acid metabolism in health and disease.Signal transduction and targeted therapy · 2023Review
- Proline is increased in allergic asthma and promotes airway remodeling.JCI insight · 2023Article
- L-Arginine, as an essential amino acid, is a potential substitute for treating COPD via regulation of ROS/NLRP3/NF-κB signaling pathway.Cell & bioscience · 2023Article
- Phenotypic characteristics of asthma and morbidity are associated with distinct longitudinal changes in L-arginine metabolism.BMJ open respiratory research · 2023Article
- Regulated Arginine Metabolism in Immunopathogenesis of a Wide Range of Diseases: Is There a Way to Pass between Scylla and Charybdis?Current issues in molecular biology · 2023Review
- Exacerbation-prone pediatric asthma is associated with arginine, lysine, and methionine pathway alterations.The Journal of allergy and clinical immunology · 2023Article
- Differences in L-arginine metabolism and asthma morbidity among asthma patients with and without obstructive sleep apnea.Respiratory research · 2022Article
- Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma: An Official American Thoracic Society Clinical Practice Guideline.American journal of respiratory and critical care medicine · 2021Article
- Article
- L-arginine as a potential GLP-1-mediated immunomodulator of Th17-related cytokines in people with obesity and asthma.Obesity science & practice · 2021Article
- Metabolic reprogramming: A driver of cigarette smoke-induced inflammatory lung diseases.Free radical biology & medicine · 2021Review
- Arginine Therapy for Lung Diseases.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
Abstract
BACKGROUNDDysregulation of l-arginine metabolism has been proposed to occur in patients with severe asthma. The effects of l-arginine supplementation on l-arginine metabolite profiles in these patients are unknown. We hypothesized that individuals with severe asthma with low fractional exhaled nitric oxide (FeNO) would have fewer exacerbations with the addition of l-arginine to their standard asthma medications compared with placebo and would demonstrate the greatest changes in metabolite profiles.METHODSParticipants were enrolled in a single-center, crossover, double-blind l-arginine intervention trial at UCD. Subjects received placebo or l-arginine, dosed orally at 0.05 mg/kg (ideal body weight) twice daily. The primary end point was moderate asthma exacerbations. Longitudinal plasma metabolite levels were measured using mass spectrometry. A linear mixed-effect model with subject-specific intercepts was used for testing treatment effects.RESULTSA cohort of 50 subjects was included in the final analysis. l-Arginine did not significantly decrease asthma exacerbations in the overall cohort. Higher citrulline levels and a lower arginine availability index (AAI) were associated with higher FeNO (P = 0.005 and P = 2.51 × 10-9, respectively). Higher AAI was associated with lower exacerbation events. The eicosanoid prostaglandin H2 (PGH2) and Nα-acetyl-l-arginine were found to be good predictors for differentiating clinical responders and nonresponders.CONCLUSIONSThere was no statistically significant decrease in asthma exacerbations in the overall cohort with l-arginine intervention. PGH2, Nα-acetyl-l-arginine, and the AAI could serve as predictive biomarkers in future clinical trials that intervene in the arginine metabolome.TRIAL REGISTRATIONClinicalTrials.gov NCT01841281.FUNDINGThis study was supported by NIH grants R01HL105573, DK097154, UL1 TR001861, and K08HL114882. Metabolomics analysis was supported in part by a grant from the University of California Tobacco-Related Disease Research Program program (TRDRP).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.